BNTC vs. TNXP, MNPR, AGE, IMNN, ABVC, MIRA, ERNA, RDHL, NNVC, and EDSA
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Tonix Pharmaceuticals (TNXP), Monopar Therapeutics (MNPR), AgeX Therapeutics (AGE), Imunon (IMNN), ABVC BioPharma (ABVC), MIRA Pharmaceuticals (MIRA), Eterna Therapeutics (ERNA), RedHill Biopharma (RDHL), NanoViricides (NNVC), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical preparations" industry.
Benitec Biopharma (NASDAQ:BNTC) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
In the previous week, Benitec Biopharma had 2 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 3 mentions for Benitec Biopharma and 1 mentions for Tonix Pharmaceuticals. Benitec Biopharma's average media sentiment score of 0.10 beat Tonix Pharmaceuticals' score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the media.
Benitec Biopharma currently has a consensus price target of $16.00, suggesting a potential upside of 129.89%. Tonix Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 3,211.26%. Given Tonix Pharmaceuticals' higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Benitec Biopharma.
Benitec Biopharma has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.
Tonix Pharmaceuticals' return on equity of -87.67% beat Benitec Biopharma's return on equity.
Benitec Biopharma has higher earnings, but lower revenue than Tonix Pharmaceuticals.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 0.5% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Tonix Pharmaceuticals received 158 more outperform votes than Benitec Biopharma when rated by MarketBeat users. Likewise, 64.20% of users gave Tonix Pharmaceuticals an outperform vote while only 63.73% of users gave Benitec Biopharma an outperform vote.
Summary
Tonix Pharmaceuticals beats Benitec Biopharma on 9 of the 14 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
